Revised forecast
Fiscal year ending March 2026 · Full yearAlthough business revenue increased on income received from analytical services and other sources, the continuation of basic research and drug discovery research, research and development expenses associated with progress in clinical development, and the recognition of cost of sales in the cancer precision medicine-related business were the main factors behind the operating loss.
Impairment loss: ¥63.216 million
| Item | Details |
|---|---|
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Previous-period results | Business revenue: ¥750.048 million; operating loss: ¥797.936 million; ordinary loss: ¥815.046 million; net loss attributable to owners of the parent: ¥815.285 million; net loss per share: ¥3.12 |
| Reason for the revision | Although business revenue increased on income received from analytical services and other sources, the continuation of basic research and drug discovery research, research and development expenses associated with progress in clinical development, and the recognition of cost of sales in the cancer precision medicine-related business were the main factors behind the operating loss. |
| Details and amount of extraordinary loss | Impairment loss: ¥63.216 million |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Business revenue increased on income received from analytical services and other sources. Meanwhile, the continuation of basic research and drug discovery research, research and development expenses associated with progress in clinical development, and cost of sales in the cancer precision medicine-related business were the main factors behind the operating loss. An impairment loss was also recorded.